Acceleron Pharma Inc. (NASDAQ:XLRN) saw a downside of -0.69% to close Tuesday at $173.78 after subtracting -$1.21 on the day. The 5-day average trading volume is 1,576,320 shares of the company’s common stock. It has gained $179.49 in the past week. An average of 2,090,005 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 954,640.
XLRN’s 1-month performance is 31.08% or $41.35 on its low of $130.07 reached on 09/16/21. The company’s shares have touched a 52-week low of $99.98 and high of $189.99, with the stock’s rally to the 52-week high happening on 09/29/21. YTD, XLRN has achieved 35.83% or $45.84. However, the current price is down -8.53%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 27, 16 days have gone by since the last insider trading activity for Acceleron Pharma Inc. (XLRN). KANGO SUJAY (EVP, Chief Commercial Officer) most recently sold 5,000 shares at $175.00 per share on Sep 27. This transaction cost the insider $875,000. SVP, CFO and Treasurer, MCLAUGHLIN KEVIN F, sold 5,370 shares at a price of $160.38 on Sep 24. Then, on Sep 23, SVP, CFO and Treasurer MCLAUGHLIN KEVIN F sold 19,630 shares at a price of $160.31 per share. This transaction amounted to $3,146,887.
Acceleron Pharma Inc. (XLRN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.XLRN stock has a beta of 0.15. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 105.25 while the price-to-book (PB) in the most recent quarter is 13.82.
Acceleron Pharma Inc.’s quick ratio for the period ended June 29 was 12.10, with the current ratio over the same period at 12.10 meaning that XLRN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -176.67%. The firm’s gross profit as reported stood at $259.83 million against revenue of $92.52 million.
For the quarterly period ending June 29 this year, Acceleron Pharma Inc.’s cash and short-term investments amounted to $287.15 million against total debt of $20.72 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -42.27% to $27.94 million, while revenue of $24.76 million was 11.38% off the previous quarter. Analysts expected XLRN to announce -$0.87 per share in earnings in its latest quarter, but it posted -$1.05, representing a -20.70% surprise. EBITDA for the quarter stood at more than -$62.63 million. XLRN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 73.02 million, with total debt at $20.72 million. Shareholders hold equity totaling $60.9 million
Let’s look briefly at Acceleron Pharma Inc. (XLRN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 67.08% to suggest the stock is trending Neutral, with historical volatility in this time period at 15.59%.
The stock’s 5-day moving average is $174.88, reflecting a -1.89% or -$3.35 change from its current price. XLRN is currently trading +31.46% above its 20-day SMA, +36.42% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +39.34% and +32.74% respectively.
Stochastic %K and %D was 62.50% and 68.07% and the average true range (ATR) pointed at 4.72. The RSI (14) points at 70.69%, while the 14-day stochastic is at 54.23% with the period’s ATR at 4.96. The stock’s 9-day MACD Oscillator is pointing at -0.15 and 0.51 on the 14-day charts.
In the most recent analyst report for Acceleron Pharma Inc. (NASDAQ: XLRN), Jefferies launched coverage with a Hold rating. Analysts offering their rating for XLRN stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate XLRN as a “sell,”, while 9 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is XLRN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $160.00 and a high of $180.00, with their median price target at $180.00. Looking at these predictions, the average price target given by analysts is for Acceleron Pharma Inc. (XLRN) stock is $177.36.